Based on in vivo and in vitro studies, we elucidate that increasing TFEB nuclear translocation, either through mTOR inhibition at the post-translational level or TFEB overexpression at the transcriptional level, is beneficial for DE treatment, due to its ability to enhance ALP-targeted clearance of AD-related proteins. This evidence concerns the gene MTOR and Alzheimer disease.